SSRN Electronic Journal
Michael Alvear
preprint
This white paper reports a stratified evidence synthesis of 31 peer-reviewed studies (2016–2026) examining ketamine and esketamine as rapid-acting treatments for suicidal ideation. Studies were classified by administration route — intravenous racemic ketamine (14 primary studies, N=1,258), intranasal esketamine/Spravato (6 primary studies, N=844), and injection routes combining intramuscular...
Emmanuel Kiiza Mwesiga, Alinaitwe Racheal, Janet Nakigudde et al.
preprint
Psychedelic side effects of ketamine limit its use for the treatment of suicide ideations. Psychedelic effects after ketamine infusion were assessed in two patients received prior electroconvulsive therapy (ECT) and one who had not. Patients who received ECT prior to the infusion had lower mean scores on all domains of the hallucinogen rating scale compared to the patient who did not receive...
Research Square
Taqwa B. Thanoon, Zeina A. Althanoon
preprint
Abstract Maternal depression during pregnancy adversely affects offspring neurodevelopment and behaviour. Typical antidepressants like selective serotonin reuptake inhibitors have limitations due to risks of crossing the placenta. Ketamine has emerged as a promising alternative treatment. This research examined ketamine's effects on offspring of maternally stressed mice. Dams were divided into...
SSRN Electronic Journal
Michael Alvear
preprint
Background: Oral and sublingual ketamine for depression is being prescribed to tens of thousands of patients through telehealth services with no FDA-approved dosing protocol, no clinical guideline covering this route of administration, and no publicly available synthesis of what clinical researchers have actually tested. A prior surveillance study of patient-reported experiences documented a...
Acacia C Parks, Amanda L Woodward, Robert D Henry et al.
BACKGROUND Major Depressive Disorder (MDD), Generalized Anxiety Disorder (GAD), and Post-Traumatic Stress Disorder (PTSD) are leading global causes of disability. Standard interventions often suffer from slow mechanisms of action, high attrition, and significant accessibility barriers. While intravenous (IV) and intranasal ketamine have emerged as rapid-acting alternatives, their high cost and...
Research Square
Katelyn Halpape, Raelle Pashovitz, Annabelle Wanson et al.
preprint
Abstract Background Ketamine is a promising therapy for treatment-resistant depression due to its rapid onset, although benefits are often transitory, with patients needing maintenance therapy to prevent relapse. Most data supporting ketamine for treatment-resistant depression refers to the intravenous route of administration, leaving alternative routes lacking in data, especially as...
Michael Alvear
preprint
This report summarizes more than 25 systematic reviews and meta-analyses published between 2020 and 2025 on ketamine-based therapies for depression. It provides a comparative analysis of intravenous (IV) ketamine, esketamine nasal spray (Spravato), and oral ketamine, highlighting differences in response rates, remission rates, speed of symptom relief, and durability of results.It also examines...
Minna Chang
Ketamine has been shown to be a novel and exciting antidepressant medication in patients with treatment-resistant depression. A complication commonly seen in frequent and heavy recreational use of ketamine is ulcerative cystitis, which presents with lower urinary tract symptoms (LUTS) and upper renal tract damage, seen in over 25% of regular users (3, 4). Although KIC is a recognised...
Research Square
Minna Chang
preprint
Abstract Ketamine has been shown to be a novel and exciting antidepressant medication in patients with treatment-resistant depression. A complication commonly seen in frequent and heavy recreational use of ketamine is ulcerative cystitis, which presents with lower urinary tract symptoms (LUTS) and upper renal tract damage, seen in over 25% of regular users (3, 4). Although KIC is a recognised...
L'Encephale
October 16, 2026
Anne Buot, Jean-Del Burdairon, Luc Mallet et al.
The use of psychedelic substances such as LSD, psilocybin, and dimethyltryptamine is currently being re-evaluated for their therapeutic potential in psychiatry. While international clinical research had started in the 2010s, France only initiated its first psychedelic trials in 2024. This study aimed to explore the knowledge, perceptions, and attitudes of French mental health professionals...